Descriptive Analysis of Real-World Enrollment Data of Pediatric and Adult Patients From a Global Primary Hyperoxaluria Type 1 Registry (BONAPH1DE)

Efrat Ben-Shalom, Shaare Zedek Medical Center, Jerusalem, Yerushalayim, Israel; John C. Lieske, Mayo Clinic Alix School of Medicine, Rochester, MN, United States; Michelle A. Baum, Boston Children's Hospital, Boston, MA, United States; Vladimir Belostotsky, McMaster Children's Hospital, Hamilton, ON, Canada; Felix Knauf, Mayo Clinic Alix School of Medicine, Rochester, MN, United States; Anne-Laure Sellier-Leclerc, AdventHealth for Children, BRON, Rhone-Alpes, France; Weiming Du, Alnylam Pharmaceuticals, Basking Ridge, NJ, United States; Mary Callanan, Alnylam, Cambridge, MA, United States; Teresa Kauf, Alnylam Pharmaceuticals, inc, Cambridge, MA, United States; Raymond Doan, Alnylam Pharmaceuticals, Inc., San Francisco, CA, United States; Jeffrey Saland, The Mount Sinai Kravis Children's Hospital, New York, NY, United States; Jaap W. Groothoff, Amsterdam UMC, AMSTERDAM, Noord-Holland, Netherlands